

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO Box 1450 Alexasotra, Virginia 22313-1450 www.repto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/534,726	11/18/2005	Braj B. Lohray	ES/4062-164	5597	
23117 7590 09/11/2008 NIXON & VANDERHYE, PC 901 NORTH GLEBE ROAD, 11TH FLOOR			EXAM	EXAMINER	
			CHANDRAKUMAR, NIZAL S		
ARLINGTON	, VA 22203		ART UNIT	PAPER NUMBER	
			MAIL DATE	DELIVERY MODE	
			09/11/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/534,726 LOHRAY ET AL. Office Action Summary Examiner Art Unit NIZAL S. CHANDRAKUMAR 1625 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 01 July 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-30 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) _____ is/are rejected 7) Claim(s) is/are objected to. 8) Claim(s) 1-30 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.

1) Notice of References Cited (PTO-892)

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Information Disclosure Statement(s) (FTO/S5/0E)
 Paper No(s)/Mail Date ________

Attachment(s)

Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.

6) Other:

5) Notice of Informal Patent Application

Art Unit: 1625

DETAILED ACTION

This application filed 11/18/2005 is a 371 of PCT/IN03/00358 11/14/2003.

Claims 1-30 are before the Examiner.

After further consideration, restriction requirement of 05/01/2008 is withdrawn in view of the following:

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to

form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single

invention to which the claims must be restricted.

Group 1, claim(s) 1-6, 14,15, drawn to compounds of formula I wherein Ar = aromatic which is not

single or fused.

Group 2, claim(s) 1-6, 14,15, drawn to compounds of formula I wherein Ar = aromatic which is single

or fused. Election of species required if this group is elected. Further restriction may be necessary

based on the heterocycle.

Group 3, claim(s) 1-6, 14,15, drawn to compounds of formula I wherein Ar = heteroaromatic which is

not single or fused. Election of species required if this group is elected. Further restriction may be

necessary based on the heterocycle.

Art Unit: 1625

Group 4, claim(s) 1-6, 14,15, drawn to compounds of formula I wherein Ar = heteroaromatic which is single or fused. Election of species required if this group is elected. Further restriction may be necessary based on the heterocycle.

Group 5, claim(s) 1-6, 14,15,drawn to compounds of formula I wherein Ar = heterocylce which is **not** single or fused. Election of species required if this group is elected. Further restriction may be necessary based on the heterocycle.

Group 6, claim(s) 1-6, 14,15,drawn to compounds of formula I wherein Ar = heterocylce which is single or fused. Election of species required if this group is elected. Further restriction may be necessary based on the heterocycle.

Group 7-12, claims 7-8, drawn to process of making compounds of Group 1-6 respectively. For example, Group 7 would correspond to process of making compunds of Group 1.

Group 13, claim 11, and claim 23 to the extent it reads on claim 11, drawn to compounds of formula

Group 14, Claim 13, drawn to process of making compounds of formula IIIa.

Art Unit: 1625

Group 15, claim 16, drawn to pharmaceutical composition containing compunds of

Group I in addition to additional therapeutic agents. Further restriction may be necessary based on additional agents.

Group 16, claims 17-21 drawn to method of treating various diseases using compounds of formula I.

If this group is elected, depending on the compound and the disease being treated, further restriction would apply.

Group 17, claims 24-29 drawn to method of treating various diseases using compounds of formula IIIa. If this group is elected, depending on the compound and the disease being treated, further restriction would apply.

Claims 9, and claims 10 and 12 and 23 (in part) are withdrawn from consideration beause the metes and bound of this claim is indefinite.

Claim 9, lines 1-3 read as follows:

 (Original) Novel compounds of formula (IIIa), , their analogs, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein 'A' represents 4-oxazolyl group

Claims 22 and 30 provide for the use of various compounds, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is

Art Unit: 1625

intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 22 and 30 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example Ex parte Dunki, 153 USPQ 678 (Bd.App. 1967) and Clinical Products, Ltd. v. Brenner, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

The inventions listed as Groups 1-17 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature is not a contribution over the prior art.

See applicant cited, WO 01/40170, which discloses

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Art Unit: 1625

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant

elects claims directed to the product, and the product claims are subsequently found allowable. withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply

Art Unit: 1625

where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP \$ 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S. CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached on 8.30 AM - 4.30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571 0272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-

Nizal S. Chandrakumar

/D. Margaret Seaman/ Primary Examiner, Art Unit 1625

786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 8

Art Unit: 1625